Frelii, Inc. (FRLI)

[TriangleCluster]

Use your DNA Blueprint to create your Health Destiny.
AI + DNA = Nutrition Perfected

https://frelii.com/

[TriangleCluster]

What kind of play is this considered? A Tech play?

[TriangleCluster]

Looks like a lot of action here lately

[TenKay]

Vican Resources, Inc. (VCAN) changed to Frelii, Inc. (FRLI)

http://otce.finra.org/DLSymbolNameChanges

[Renee]

VCAN: effective March 8,2017 a one for 1,000 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[linkvest]

Nothing happening here just like over at the other scam Denos is running at FLST... Denos is nothing more than another Scam Artist Attorney that is fleecing the share holders on all his company scans.

Denos is just another dirt bag pinkie scammer...

[wesvester]

What happened today. Wow

[Circuit_Racer]

i have been watching this junker for a lil while now lol...

someones loading up imo, and its definitely not me, id rather catch the run up for a flip then buy an hold for something to happen.

my 2 cents, GLTA

[Raphael De La Ghetto]

Is this thing active, besides the almost 2 billon shares converted, and loss after loss! could this be a good flip?

[22hornet]

DTC suspended services...do you know why?

Is this the same thing as a 'chill'?

[VIPR]

DTC has suspended all services, except Custody Services, for the below referenced issues. The suspensions are effective December 9, 2011.


CUSIP
08265R103 284683208 40430N204 88342Q203 925606105 987536109
SECURITY NAME
Bentley Sports, Inc. Eldorado Exploration, Inc. HS3 Technologies, Inc. Therma-Med, Inc.
Vican Resources, Inc. Younger America, Inc.

Questions regarding DTC’s Important Notice should be directed to the Office of Corporate Regulatory Compliance at [e-mail].

[VIPR]

Form 10-Q for VICAN RESOURCES, INC.

21-Nov-2011

Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements

This report contains forward-looking statements that involve risks and uncertainties. We use words such as anticipate, believe, plan, expect, future, intend and similar expressions to identify such forward-looking statements. You should not place too much reliance on these forward-looking statements. Our actual results are likely to differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us described in the Risk Factors section included in this Report on Form 10-Q.

Plan of Operation

Prior to July 31, 2009, we were a development stage company named "Cancer Detection Corporation" which sought to provide research and development to potential cancer and related pathogen vaccines. This business was discontinued in July 2009, when the Company reorganized under the name of "Tremont Fair, Inc." and operated as a real estate services company. In May 2011, the Company was further reorganized when we acquired all of the outstanding shares of Vican Trading, Inc., a Delaware corporation (hereafter, "Vican-Delaware"). Vican-Delaware is a purchaser and seller of metals, ores, and other commodities throughout North America. In connection with the acquisition of Vican Delaware, we changed our name from "Tremont Fair, Inc." to "Vican Resources, Inc." and appointed Lorne Kalisky, Chene Gardner, and Corey Safran as our Chief Executive Officer, Chief Financial Officer, and Secretary, respectively. We expect that the business of Vican Delaware will predominate within the consolidated group in the future.

Liquidity and Capital Resources

As of September 30, 2011, the Company's primary source of liquidity consisted of $70,437 in cash and cash equivalents. The Company holds most of its cash reserves in local sweep accounts with local financial institutions. Since inception, the Company has financed its operations through a combination of short and long-term loans, and through the private placement of its common stock.

The Company has sustained significant net losses which have resulted in a total stockholders' deficit at September 30, 2011 of $3,822,224 and is currently experiencing a substantial shortfall in operating capital which raises doubt about the Company's ability to continue as a going concern. The Company anticipates a net loss for the year ended December 31, 2011 and with the expected cash requirements for the coming months, without additional cash inflows from an increase in revenues combined with continued cost-cutting or a receipt of cash from capital investment, there is substantial doubt as to the Company's ability to continue operations.

There is presently no agreement in place with any source of financing for the Company and there can be no assurance that the Company will be able to raise any additional funds, or that such funds will be available on acceptable terms. Funds raised through future equity financing will likely be substantially dilutive to current shareholders. Lack of additional funds will materially affect the Company and its business, and may cause the Company to cease operations. Consequently, shareholders could incur a loss of their entire investment in the Company.


Table of Contents
Results of Operations

Until the reorganization of the Company in July 2009, we were considered a development stage company for accounting purposes, since we had not yet received any revenues from operations. Effective September 1, 2009, Tremont Fair Holdings, Inc. acquired two property management agreements from Creekstone Equity Management, a company controlled by Cyrus Boga (the "Management Agreements").

Revenues. For the three months ended September 30, 2011, net revenues were $11,049,129 compared to $38,325for the three months ended September 30, 2010. For the nine months ended September 30, 2011, net revenues were $16,852,874 compared to $120,221 for the nine months ended September 30, 2010. The increase is due to the acquisition Vican Trading, Inc. during the second quarter of 2011. The Company expects that revenues will continue to remain at these levels in the future.

Cost of Sales. Cost of sales for the three and nine months ended September 30, 2011 were $10,735,826 and $16,211,895, respectively, compared to $-0- for the three and nine months ended September 30, 2010. Cost of sales correlates with the volume of revenues for the periods.

Selling General and Administrative Expenses ("SG&A"). Our SG&A expenses for the three months ended September 30, 2011was $352,335 compared to $111,458 for the three months ended September 30, 2010. For the nine months ended September 30, 2011, SG&A expenses were $1,502,541 compared to $476,900 for the nine months ended September 30, 2010.

Other Expense.The Company had net other expenses of $4,218,211 for the nine months ended September 30, 2011. The largest item in this category was the write off of goodwill associated with the acquisition of Vican Trading Inc. which amounted to $3,837,934.

Net Loss. We had a net loss for the nine months ended September 30, 2011 of $5,054,093 compared to a net loss of $360,810 for the nine months ended September 30, 2010.

Off-Balance Sheet Arrangements

We do not have any off balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of any contingent assets and liabilities. We base our estimates on various assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. On an on-going basis, we evaluate our estimates. Actual results may differ from these estimates if our assumptions do not materialize or conditions affecting those assumptions change.


Table of Contents
We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements:

Revenue Recognition

Revenue from management services is recognized when service is completed.

Stock-Based Compensation

The Company sometimes grants shares of stock for services. These grants are accounted for based on the grant date fair values.

[VIPR]

Boy, That didn't take long....

Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec


Item 1.01 Entry into a Material Definitive Agreement

On October 12, 2011, Vican Resources, Inc. (the "Company") entered into an agreement with 6961916 CANADA INC. (hereafter, "696"), a corporation owned and controlled by Lorne Kalisky, our Chief Executive Officer and controlling shareholder, granting 696 the right and option (the "Option") to purchase all of the shares of Vican Trading, Inc. held by the Company. Vican Trading, Inc., which was acquired on May 26, 2011, is a wholly-owned subsidiary of the Company specializing in the purchase and sale of metals and other commodities. The Option granted to 696 becomes exercisable in the event that the Company does not raise at least $250,000 in a private placement of its debt or equity securities within 60 days. The exercise price to be paid by 696 in the event of an exercise of the Option is the redemption and cancellation of all of the shares of common, Series B, and Series C Preferred Stock held by 696.

On October 12, 2011, the Company entered into an agreement with two holders of its Series B Preferred Stock, one of whom is 696, the Company's controlling shareholder and a holding company of Lorne Kalisky, the Company's Chief Executive Officer, to convert such holdings into an aggregate of 325,000 shares of common stock of the Company upon the approval of the Financial Industry Regulatory Authority ("FINRA") of a 100-1 reverse split of the Company's outstanding shares that was requested in August, 2011.

Item 3.02 Unregistered Sales of Equity Securities

On October 12, 2011, the Company issued an aggregate of 8,000,000 shares of Series C Preferred Stock to 6 persons in privately negotiated transactions. Two of the recipients of the Series C Preferred Stock were Corey Safran, a director and the Secretary of the Company, and 696, the Company's controlling shareholder and a holding company of Lorne Kalisky, the Company's Chief Executive Officer. The Series C Preferred Stock converts into common stock of the Company on a one-for-one basis upon the approval by FINRA of a 100-1 reverse split of the Company's outstanding shares that was requested in August, 2011. No solicitation was made in connection with these transactions and no underwriting discounts were made or given. The Company believes that the issuance of the Series C Preferred Stock was a transaction not involving a public offering and was exempt from registration with the Securities and Exchange Commission pursuant to Rule 4(2) of the Securities Act of 1933.

They didn't mention WHO the other (4) were did they........?????????????????

[VIPR]

Welcome to the VCAN Board!!!!!!

[VIPR]

Stock getting a lot of volume lately, definitely one for the watchlist!

[VIPR]

Has got to be something interesting going on with this one...stock going to $1?

[VIPR]

Stock looks pretty volatile on 2 month chart

[VIPR]

A lot of action in this stock here lately...hmmmm

[hmitwatch]

Klok has once again destroyed shareholder value (this time ALTO) and perhaps here with VCAN is where he will set his sights next on promises that will never come true and shareholder value getting destroyed. Buyer beware. Do your DD on Mark Klok and his extensive horrible history.

[hmitwatch]

Welcome to Klok's latest shell designed to empty pockets for his own benefit while never providing anything but promises and lack of follow thru. Buyer beware. Do your dd on Klok and his EXTENSIVE history of shady transgressions.

[hmitwatch]

Well looky who just got his hands on this company. See how long it takes before Klok runs this one into the ground. The legend continues.



http://google.brand.edgar-online.com/DisplayFilingInfo.aspx?Type=HTML&text=%2526lt%253bNEAR%252f4%2526gt%253b%28%22MARK+D.%22%2c%22KLOK%22%29&FilingID=7887765&ppu=%2fPeopleFilingResults.aspx%3fPersonID%3d4729296%26PersonName%3dMARK%2520D.%2520KLOK

[RaisingKahne]

Symbol: TMTF
Issuer: Tremont Fair, Inc.

Insider Name: Thomas John Darrow (Pres,Sec,Principle Fin.Officer)
Shares: 225,000
Price: .01
Value($): 1,575
Trade Date: 2011-04-28

and

Insider Name: Klok Mark Daniel (Director)
Shares: 30,000,000
Price: .01
Value($): 210,000
Trade Date: 2011-04-28

and

Insider Name: Sierra Vista Holdings, Inc. (10% Owner)
Shares: 30,000,000
Price: .01
Value($): 210,000
Trade Date: 2011-04-28

Date Open High Low Close Volume Adj Close
2011/05/02 0.029 0.029 0.029 0.029 4,715 0.029
2011/04/29 0.015 0.020 0.013 0.020 98,000 0.020
2011/04/28 0.020 0.020 0.015 0.015 1,494,475 0.015
2011/04/27 0.030 0.030 0.030 0.030 - 0.030

[westcoastcash]

The retiring of 70 million shares
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7865766

[westcoastcash]

This is a pretty tightly held little company and wouldn't be surprised if something else is going on in the background. This could easily move up with any kind of news on an aquisition or take over etc. It's nice to be able to get in before the mad rush..LOL

[stockmarketmadness]

neither did I, but someone did.

[westcoastcash]

I read that filing and couldn't see any reason for the increase in price.........

[stockmarketmadness]

this is why it moved:

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7863394

[westcoastcash]

Up over 600%.......can't find any news.....must be something in the wind

[westcoastcash]

This ones already been rolled back 20 to 1.........80 million restricted for the vend in and control to Tremont Fair......Not much of a float so should move up quite easily.......

[canirolf]

Couldn't find any info of why is going up, have you guys found something?
Thanks

[buxmaker]

Nice breakout underway in TMTF

[westcoastcash]

Looks like this one is starting to wake up.........

[westcoastcash]

Looks interesting....

[vanfielding]

Any news for this company? I noticed that there had been some SEC filings in the past couple of months besides the 10Q. New shareholders, new board. Wish they wuld provide better information.

[vanfielding]

saw the 10Q - good stuff buried inside. why dont these guys put out more news?? seems things are happening at the company

[mrs trader]

I think there may have been 3rd party actions , As well there are several shareholders that hold a significant chuck of stock. IMO

[ben harrison]

What do you believe our chances are of this company being a success? I think the 3rd. party validation is the first hurdle that has to happen. Your thoughts please.

[mrs trader]

I hope to see some posters soon . If your looking for info just post and I will do my best to get answers. Thannks

[mrs trader]

The I box needs updating!

[mrs trader]

needing to have diolog with the company!

[mrs trader]

would like to see some good news!

[mrs trader]

good afternoon posters

[B_Wayne]

What a mess this stock has become...

[monda2frida]

Xpention Genetics Announces Plans for Reverse Stock Split and Name Change as Prelude to New Investment

CONIFER, CO, Aug 12, 2008 (MARKET WIRE via COMTEX) -- Xpention Genetics, Inc. (OTCBB: XPNG) today announced that a majority of its shareholders approved a proposal to authorize the Board, in its discretion, to effect a reverse split of Xpention's issued and outstanding common stock at a ratio ranging from one-for-ten to one-for-twenty without further action by shareholders and to change the name of the company to Cancer Detection Corporation. As of the end of business on July 24, 2008, there were approximately 96.5 million shares of Xpention's common stock outstanding. The reverse split will not change the number of shares of Xpention's preferred stock authorized, which will remain at 10 million.
The Company has recently retired $100,000 of convertible debt via conversion into equity. As a result, the Company is limited in its ability to obtain the additional equity capital necessary to continue its research activities as substantially all authorized shares of common stock have been issued. The purpose of the reverse split is to decrease the number of outstanding shares, thereby permitting the Company an opportunity to raise additional capital. Initially, the reverse split would not affect any individual stockholder's percentage ownership interest in the Company; however, if the Company is successful in raising additional equity capital the percentage ownership interest of any individual stockholder would be reduced. The purpose of the name change is to better reflect the Company's business. The Company has received conditional commitments for additional equity capital from two existing stockholders and plans to use the funds primarily for research activities, including validation of its primary technology.

David Kittrell, President and CEO, commented, "The ability to raise additional equity capital to fund our ongoing research, including the validation of our licensed p65 technology, is critical to our ability to execute our business plan to commercialize this technology. The Board believes that it is in the best long-term interest of the Company and our stockholders to raise the additional capital necessary to continue our research activities which, if successful, would improve both the Company's value as well as each individual stockholder's investment despite having a reduced ownership percentage of the Company. We are encouraged that two of our existing stockholders have tentatively agreed to increase their investment into the Company to fund the research necessary for us to move forward toward the goal of producing cancer detection tests for canines and humans. Our name change will more accurately depict our mission and may broaden our stock's appeal to a wider range of investors."

Treatment of Stock Options, Warrants and Convertible Notes

The number of common shares into which any of Xpention's outstanding stock options, warrants and convertible notes are convertible, as well as the relevant exercise or conversion price per share, will be proportionately adjusted to reflect the reverse split.

Fractional Shares

Xpention will not issue any fractional shares of its common stock as a result of the reverse split. Instead, the company will round up any fractional interest to the next whole number of shares. No shareholder will receive less than one share of common stock after the reverse split.

Obtaining New Stock Certificates

Xpention will adopt a new stock certificate in connection with the implementation of the reverse split.

Holladay Stock Transfer, Inc. has been retained to manage the exchange of stock certificates. Shareholders of record will receive a letter of transmittal providing instructions for the exchange of their certificates as soon as practicable following the effectiveness of the reverse split. Shareholders who hold their shares in "street name," will be contacted by their banks or brokers with any instructions. For further information, shareholders and securities brokers should contact Holladay at 480-481-3940.

About Xpention Genetics, Inc.

Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods. Xpention Inc., a wholly owned subsidiary of Xpention Genetics, Inc. and The University of Texas M. D. Anderson Cancer Center signed a Patent and Technology License Agreement granting Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65, which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.



Contact:
Trevor Justus
Windfall Communications, LLC
866-590-6589


SOURCE: Xpention Genetics, Inc.




Copyright 2008 Market Wire, All rights reserved.
-0-

SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
< Back









All information contained herein is provided "as is." Pink OTC Markets Inc. makes no representation or warranty, expressed or implied, as to the accuracy, timeliness, or completeness of the information provided herein. Neither Pink OTC Markets Inc., nor its directors, officers, employees, or third party data suppliers, shall bear any responsibility or liability to verify the information and/or its source or for the use, misuse, or inability to use the information provided. None of the foregoing parties shall be liable to any third-party claims or losses of any nature. Accordingly, investors should not use this information as the basis for making an investment decision. Please see Risk Warning and Terms of Service for more information.

Home | Quotes & News | Market Activity | OTC Company Search | Products & Services | OTC Guide | About Pink OTC Markets | Site Map
© Copyright 2008, Pink OTC Markets Inc. All Rights Reserved.
Terms of Service | Linking & Framing Terms | Trademarks | Privacy Statement | Risk Warning | Contact Regulators

[buhg1b]

Nothing new from the company lately. Very light volume.

[buhg1b]

What Is This Thing Called "Me"?
Part 10: The Temporally Synchronized, Binary, Organic Living Engine
by Daniel J. Schneck
March 2008 - American Laboratory

The human body has a sophisticated, delicately balanced, coordinated, and synchronized hierarchy of operating time scales, each intended to satisfy specific physiologic needs of the organism. Interestingly, these time scales are correlated almost one-to-one with corresponding levels of organization of the human body. Thus, their specific ranges can be conveniently classified as encompassing:

-10^-6 to 10^-3 sec: Atomic/molecular enzyme kinetics (biochemical catalysis). For example, consider the activity of the red blood cell enzyme carbonic anhydrase, ...

see iBox for the full article.

www.americanlaboratory.com

[buhg1b]

Delisting

Considering all the late filings (see the iBox or www.sec.gov), I wonder if Xpention will be delisted from the OTCBB this year...

[buhg1b]

Technicals

http://quotes.barchart.com/texpert.asp?sym=xpng&what=opinion

Composite Indicator
Trend Spotter TM Sell

Short Term Indicators
7 Day Average Directional Indicator Sell
10 - 8 Day Moving Average Hilo Channel Sell
20 Day Moving Average vs Price Sell
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Sell
20-Day Average Volume - 56970

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Sell
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 25% - Sell
50-Day Average Volume - 69688

Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Sell
50 - 100 Day MACD Oscillator Sell

Long Term Indicators Average: 67% - Sell
100-Day Average Volume - 53612

Overall Average: 64% - Sell

[buhg1b]

Liquidity

We have never received revenue from our operations. We have historically relied on equity and debt financings to fund our capital resource requirements. We have experienced net losses since inception. We do not believe that we are a candidate for conventional debt financing and we have not made arrangements to borrow funds under a working capital line of credit. We will be dependent on additional financing to continue our research and development efforts.

The report of our independent accountants on our financial statements at May 31, 2007 contains a qualification about our ability to continue as a going concern. This qualification is based on our lack of operating revenue and limited working capital, among other things. We remain dependent on receipt of capital from outside sources, and ultimately, generating revenue from operations, to continue as a going concern.

All of our investment in research and development activities has been expensed, and does not appear as an asset on our balance sheet. From inception to November 30, 2007 we have spent $937,601 on our research and development efforts to commercialize the p65 technology.

As of November 30, 2007, our working capital deficit of $(592,933) was comprised of current assets of $9,746 and current liabilities of $602,679. This represents a decline in working capital of $121,758 compared to the deficit of $(471,175) at fiscal year end May 31, 2007.

All of our capital resources to date have been provided through the sale of equity securities, proceeds from notes payable and convertible debentures, and advances from stockholder. From inception through November 30, 2007, we received $475,100 in cash through issuance of our common stock. Since we have not generated any cash from operations, we have relied on sale of equity and borrowings to fund all of our capital needs.

The Company's ability to pay its accounts payable and accrued expenses and repay its borrowings is dependent upon receipt of new funding from stockholder advances, private placements or debt financing. One of our stockholders has periodically advanced funds to us to meet our working capital needs. The stockholder is under no obligations to continue these advances. During September, 2007, the stockholder advanced an additional $5,000 to us.

Net cash used in operating activities was $35,123 during the six months ended November 30, 2007, compared to $35,392 during the corresponding period of the prior year. There were no material differences in our operations between the two periods.

Net cash provided by financing activities during the six months ended November 30, 2007 was $10,600, compared to $16,200 during the comparable period of the prior year. We received an advance of $5,000 from a stockholder during the six months ended November 30, 2007, as compared to $8,200 during the six months ended November 30, 2006. In addition, we received proceeds of $5,600 from a convertible bridge loan from The Regency Group LLC, a related party, during the six months ended November 30, 2007. In the comparable period in 2006 we received proceeds of $8,000 from The Regency Group, LLC. During the period ended November 30, 2007, we modified the terms and conditions of previous borrowings from The Regency Group LLC. All of the bridge loans from The Regency Group LLC are payable on December 1, 2007, or earlier date if financing of $1,000,000 is obtained. The borrowings are convertible into common stock of the Company at a rate of $0.0035 per share. Subsequent to November 30, 2007, the due dates of the borrowings were extended to the earlier of January 31, 2008, or the date on which financing of at least $1,000,000 is obtained.

[buhg1b]

Plan of Operation (from filing)

The Company, through its wholly-owned subsidiary, holds the exclusive worldwide license for patented technology for the detection of cancer based on a tumor marker known as "p65" which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions. "p65" is believed to be a protein required in the early development of numerous cancers and appears from early research to provide a strong indication of tumor growth in both canines and humans. It also appears to have a direct correlation to tumor size/mass making it a promising marker for both early detection of malignant tumor formation as well as a useful tool for monitoring therapy and remission. Initially, the Company plans to develop an immunological test as well as a molecular assay for detection of cancer in canines. The Company also plans to develop both immunological and molecular tests for detection of human cancers as well as therapeutic treatments and vaccines.

The Company contracts with third party research organizations to conduct its research activities. During June 2007, the Company entered into an Assay Revalidation / Redevelopment Proposal with Future Focus, an independent testing organization. The project calls for third party validation of the research results presented in the final report from the University of Texas Health Science Center at San Antonio ("UTHSCSA") and technology transfer of the current assay plus assay reformatting and sample analysis. On August 15, 2007, the Company announced that the researchers had been unable to replicate the results obtained at UTHSCSA.

As a result of the initial disappointing results, the Company is reviewing its planned research activities for the development of an immunological canine cancer detection test. The Company also continues to evaluate various options for commercialization of its products; however, it is not anticipated the Company will generate any revenues from commercialization of its technology during the next twelve months.

Management does not believe that the Company's current capital resources will be sufficient to fund its operating activity and other capital resource demands during fiscal year 2008. The Company's ability to continue as a going concern is contingent upon its ability to obtain capital through the sale of equity or issuance of debt, joint venture or sale of its assets, and ultimately attaining profitable operations.

The Company is presently seeking additional debt and equity financing to provide sufficient funds for payment of amounts due under research contracts as well as accrued but unpaid professional fees and administrative expenses and to fund ongoing research and operations.